Biontech Se ADR (BNTX)
$101.59 4.26 (4.02%)
16:24 EST BNTX Stock Quote Delayed 30 Minutes
Previous Close -
Market Cap -
PE Ratio -
Volume (Avg. Vol.) 2.86M
Day's Range 97.31 - 104.99
52-Week Range 28.00 - 131.00
Dividend & Yield N/A (N/A)
BNTX Stock Predictions, Articles, and Biontech Se ADR News
- From InvestorPlace
- From the Web
It’s a relief to know Covid-19 vaccines are on the way. But there are plenty of other great biotechs that have been overlooked in the market frenzy.
Buying strong vaccine stocks at the forefront of the scientific race to treat Covid-19 will help any long-term portfolio in 2021.
In light of a collaboration with a major drugmaker and a fast-track toward possible FDA approval, BNTX stock is practically irresistible.
Simply put, blockchain is the safest way to store and transfer information ever created, which makes it ideal for tracking vaccines.
With a new Covid vaccine update today, how do the Moderna and Pfizer coronavirus vaccines compare? Dive in here.
We’re heading into the seasonally strong time of year, and as Thanksgiving week approaches, it is likely the market will take off. So, if you have any cash to invest, please be invested before Thanksgiving!
After the volatility of 2020, analysts see some calm in the offing. Here are 5 companies to invest in on those prospects.
Shares of BNTX stock are flying on Monday after BioNTech and Pfizer announced extremely positive results from their Covid-19 vaccine trials.
Pfizer stock is rallying higher Monday on coronavirus vaccine results, and it's taking the rest of the stock market with it.
While I’d like to tell you Inovio Pharmaceuticals is a blood-in-the-streets opportunity, I can’t. Avoid INO stock for now.
BNTX stock is a high-risk high-return investment. BioNTech shares will likely to range-trade in the short run.
Pfizer stock and partner BioNTech are rallying Monday morning on news the two companies could vaccinate Americans before the end of 2020.
While NVAX stock could race higher on news in coming days of its clinical trials results, play this one safe with a trailing stop loss to safeguard any wins you have to date.
Inovio Pharmaceuticals remains one of the most undervalued of the vaccine makers. Even after a 455% run higher, INO stock has plenty of upside fueled by plenty of catalysts.
The race is on for a coronavirus cure as the pandemic sickens millions. These three vaccine stocks are in the investing spotlight right now.
Neon Therapeutics (NTGN ) news for Thursday about a $67.00 million deal with BioNTech (BNTX) has NTGN stock soaring on Thursday.
Navellier RatingsPowered by Portfolio Grader